Nutex Health Inc. (NUTX) is a Great Momentum Stock: Should You Buy?
Does Nutex Health Inc. (NUTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why 'Trend' Investors Would Love Betting on Nutex Health (NUTX)
Nutex Health (NUTX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Surging Earnings Estimates Signal Upside for Nutex Health (NUTX) Stock
Nutex Health Inc. (NUTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Nutex Health: A 'Strong Buy' Amid Margin Expansion, Regulatory Tailwinds (Upgrade)
Nutex Health upgraded to "Strong Buy" as margin expansion and patient volume growth drive bullish outlook. Despite a 13% YoY revenue decline, Q2 saw 9.6% patient volume growth and significant, sustainable operating cost reductions. CMS administrative fee cuts and the HaloMD contract amendment are expected to lower normalized costs by 25%–30% in future periods.
Nutex Health Inc. (NUTX) Q2 2026 Earnings Call Transcript
Nutex Health Inc. (NUTX) Q2 2026 Earnings Call Transcript
Nutex Health Q2 Earnings Call Highlights
Nutex Health NASDAQ: NUTX reported higher second-quarter profitability and adjusted EBITDA despite lower revenue, as the company benefited from reduced arbitration-related costs, lower stock-based compensation and continued patient-volume growth.
Nutex Health Has A Healthy Pulse And Shows Strong Signs Of Life For Further Gains
Nutex Health is rated Buy, with a DCF-based price target of $199.31, offering 19.8% upside from $166.40. NUTX's revenue surged from $247.6M in FY2023 to $880.0M TTM ended March 31, 2026, driven by effective use of the No Surprises Act's IDR process. Liquidity and leverage metrics have improved, with debt-to-equity falling below 1.0 and the current ratio at 3.1 in the TTM period.
Nutex Health Inc. (NUTX) Q1 2026 Earnings Call Transcript
Nutex Health Inc. (NUTX) Q1 2026 Earnings Call Transcript
Nutex Health Inc. (NUTX) Q4 2025 Earnings Call Transcript
Nutex Health Inc. (NUTX) Q4 2025 Earnings Call Transcript
Nutex Health: The $387 Million Receivables Problem And The Legislative Silver Bullet
Nutex Health is rated a buy, driven by the potential passage of the No Surprises Enforcement Act. NUTX's $387 million in receivables could rapidly convert to cash if the bill passes, eliminating a key valuation overhang. The company trades at 5.2x P/E despite 49% projected 2026 revenue growth and a 27% TTM operating margin, reflecting market skepticism over payment collections.
Nutex Health Inc. (NUTX) Discusses Restated 2024 Results and Combined Second and Third Quarter 2025 Financial Performance Transcript
Nutex Health Inc. (NUTX) Discusses Restated 2024 Results and Combined Second and Third Quarter 2025 Financial Performance Transcript
Nutex Health: Fairly Valued After Pullback, But Wait For A More Ideal Entry Point (Rating Upgrade)
Nutex Health Inc. recently posted Q2 and Q3 results, showing strong revenue growth and operating cash flow. NUTX's accounts receivable balance continues to rise, raising questions about the collectability of revenue booked under the No Surprises Act. NUTX's valuation metrics compare very favorably to its peers across the board.
